Program
daprodustat
Also written as “GSK1278863”, “Daprodustat” and “Daprodustat (GSK1278863)”.
Its studies are mostly in Anemia · Diabetic Foot · Peripheral Vascular Diseases · Tendon Injuries, led by 2 companies.
Drug pageGSK1278863: every studyAll 34 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 320 open or running | phase 3since Jun 2, 2016 | Jun 16, 2011 | none ahead |
| Qilu Pharmaceuticalits history only | 11 open or running | phase 3since Dec 10, 2025 | Dec 10, 2025 | May 2027phase 3 · NCT07300111 |
Also a collaborator on its studies: Q2 Solutions, Quintiles, HemoCue and PPD DEVELOPMENT, LP.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of GlaxoSmithKline only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 15 studies since Jun 16, 2011.
- Feb 19, 2015Phase 1 study in AnemiaNCT02371603 · 70 enrolled · United States
- Jun 9, 2015Named daprodustatINNProposed as its International Nonproprietary Name in WHO's List 113 · before, GSK1278863
- Feb 11, 2016Phase 2 study in AnemiaNCT02689206 · 103 enrolled · United States, Canada, Germany and more
- Jun 2, 2016Phase 3 study in AnemiaNCT02791763 · 355 enrolled · Japan
- Jul 8, 2016Phase 3 study in AnemiaNCT02829320 · 28 enrolled · Japan
- Aug 19, 20162 phase 3 studies in AnemiaNCT02876835, NCT02879305
- Jan 20, 2017Phase 2 study in AnemiaNCT03029247 · 105 enrolled · United States
- Jan 20, 2017Phase 3 study in AnemiaNCT03029208 · 312 enrolled · United States, Argentina, Australia and more
- Jul 17, 20172 phase 1 studies in AnemiaNCT03239522, NCT03223337
- Jan 8, 20182 phase 3 studies in AnemiaNCT03409107, NCT03400033
- Feb 20, 2018Phase 2 study in AnemiaNCT03446612 · 6 enrolled · United Kingdom
- Mar 1, 2018Phase 2 study in AnemiaNCT03457701 · 15 enrolled · United States
- Apr 4, 2018Phase 1 study in AnemiaNCT03493386 · 64 enrolled · Japan
- Nov 18, 2020Phase 1 study in AnemiaNCT04640311 · 259 enrolled · United States
- Jan 4, 2023Phase 3 study in AnemiaNCT05682326 · 4 enrolled · Japan, South Korea
TargetBeta
“Hypoxia-inducible factor prolyl hydroxylase inhibitor”ChEMBL 37, by rule
Other programs on the same 4 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| roxadustatrule | Astellas Pharma | phase 4 | 47 |
Studies
All 32 GlaxoSmithKline leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05682326Anemia · Japan, South Korea | 3 | Completed | Oct 18, 2024 | 4 |
| NCT04640311Anemia · United States | 1 | Completed | May 18, 2021 | 259 |
| NCT03493386Anemia · Japan | 1 | Completed | Jun 9, 2018 | 64 |
| NCT03457701Anemia · United States | 2 | Completed | Jul 5, 2022 | 15 |
| NCT03446612Anemia · United Kingdom | 2 | Terminated | May 29, 2019 | 6 |
| NCT03409107Anemia · United States, Argentina, Australia and more | 3 | Completed | Oct 7, 2020 | 614 |
| NCT03400033Anemia · United States, Argentina, Australia and more | 3 | Completed | Jun 19, 2020 | 407 |
| NCT03223337Anemia · United States | 1 | Completed | Aug 20, 2018 | 37 |
| NCT03239522Anemia · United Kingdom | 1 | Completed | Nov 28, 2017 | 6 |
| NCT03029247Anemia · United States | 2 | Completed | Jul 9, 2020 | 105 |
| NCT03029208Anemia · United States, Argentina, Australia and more | 3 | Completed | Sep 24, 2020 | 312 |
| NCT02879305Anemia · United States, Argentina, Australia and more | 3 | Completed | Nov 9, 2020 | 2,964 |
| NCT02876835Anemia · United States, Argentina, Australia and more | 3 | Completed | Apr 19, 2021 | 3,872 |
| NCT02829320Anemia · Japan | 3 | Completed | May 16, 2017 | 28 |
| NCT02791763Anemia · Japan | 3 | Completed | Oct 26, 2018 | 355 |
| NCT02689206Anemia · United States, Canada, Germany and more | 2 | Completed | Jan 25, 2017 | 103 |
| NCT02371603Anemia · United States | 1 | Completed | Aug 12, 2015 | 70 |
| NCT02293148Anemia · United States | 1 | Completed | Mar 10, 2015 | 61 |
| NCT02231190Tendon Injuries · United States | 1 | Completed | Jun 12, 2015 | 26 |
| NCT02243306Anemia · United States | 1 | Completed | May 10, 2017 | 8 |
| NCT02075463Anemia · United States | 2 | Terminated | Mar 16, 2016 | 15 |
| NCT02019719Anemia · Japan | 2 | Completed | Aug 6, 2014 | 97 |
| NCT01977573Anemia · United States, Australia, Canada and more | 2 | Completed | May 1, 2015 | 252 |
| NCT01977482Anemia · United States, Australia, Canada and more | 2 | Completed | Feb 1, 2015 | 216 |
| NCT01920594Surgical Procedures · United States, Canada | 2 | Completed | Oct 8, 2014 | 57 |
| NCT01831804Diabetic Foot · United States | 1 | Completed | Feb 10, 2017 | 65 |
| NCT01673555Anemia · United States | 1 | Completed | Nov 19, 2012 | 49 |
| NCT02135848Peripheral Vascular Diseases · United States | 2 | Completed | Nov 1, 2011 | 46 |
| NCT01587924Anemia · United States, Canada, Denmark and more | 2 | Completed | May 27, 2013 | 80 |
| NCT01587898Anemia · United States, Canada, Germany | 2 | Completed | May 7, 2013 | 72 |
| NCT01406340Anemia · United States | 1 | Terminated | Aug 31, 2013 | 22 |
| NCT01376232Anemia · India | 1 | Completed | Dec 20, 2010 | 23 |
How it is read
Names in the registry
- “GSK1278863”, 15 entries
- “Daprodustat”, 9 entries
- “Daprodustat (GSK1278863)”, 2 entries
- “Daprodustat tablets”, 1 entry
- “1 to 4 mg tablets of GSK1278863”, 1 entry
Codes read as this program: GSK1278863.
Conditions, from the studies’ own filings
- Anemia, 29 studies
- Diabetic Foot, 1 study
- Peripheral Vascular Diseases, 1 study
- Tendon Injuries, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.